tiprankstipranks
Trending News
More News >
Carisma Therapeutics (CARM)
NASDAQ:CARM
US Market
Advertisement

Carisma Therapeutics (CARM) Stock Forecast & Price Target

Compare
1,700 Followers
See the Price Targets and Ratings of:

CARM Financial Forecast

CARM Earnings Forecast

Next quarter’s earnings estimate for CARM is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.23. CARM beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.
Next quarter’s earnings estimate for CARM is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.23. CARM beat its EPS estimate 33.33% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.

CARM Sales Forecast

Next quarter’s sales forecast for CARM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CARM beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.13% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.
Next quarter’s sales forecast for CARM is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CARM beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.13% of the time in the same period. In the last calendar year CARM has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
Hold
Reiterated
04/01/25
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (NASDAQ: CARM), BioCardia (NASDAQ: BCDA) and Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN)
D. Boral Capital Analyst forecast on CARM
D. Boral Capital
D. Boral Capital
$12$1
Buy
257.14%
Upside
Reiterated
04/01/25
Carisma Therapeutics price target lowered to $1 from $12 at D. Boral CapitalCarisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital
Evercore ISI Analyst forecast on CARM
Evercore ISI
Evercore ISI
$0.7
Hold
150.00%
Upside
Assigned
12/11/24
Carisma Therapeutics (CARM) Receives a Hold from Evercore ISI
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
Hold
Reiterated
04/01/25
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (NASDAQ: CARM), BioCardia (NASDAQ: BCDA) and Guardian Pharmacy Services, Inc. Class A (NYSE: GRDN)
D. Boral Capital Analyst forecast on CARM
D. Boral Capital
D. Boral Capital
$12$1
Buy
257.14%
Upside
Reiterated
04/01/25
Carisma Therapeutics price target lowered to $1 from $12 at D. Boral CapitalCarisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital
Evercore ISI Analyst forecast on CARM
Evercore ISI
Evercore ISI
$0.7
Hold
150.00%
Upside
Assigned
12/11/24
Carisma Therapeutics (CARM) Receives a Hold from Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Carisma Therapeutics

1 Month
xxx
Success Rate
0/4 ratings generated profit
0%
Average Return
-27.65%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -27.65% per trade.
3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-17.85%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -17.85% per trade.
1 Year
Jason KolbertD. Boral Capital
Success Rate
1/4 ratings generated profit
25%
Average Return
-21.20%
reiterated a buy rating 6 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.20% per trade.
2 Years
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-21.20%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -21.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CARM Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Sep 25
Strong Buy
3
1
1
0
0
Buy
0
0
0
0
0
Hold
7
4
6
11
12
Sell
9
4
3
0
0
Strong Sell
0
2
3
3
1
total
19
11
13
14
13
In the current month, CARM has received 0 Buy Ratings, 12 Hold Ratings, and 1 Sell Ratings. CARM average Analyst price target in the past 3 months is 0.50.
Each month's total comprises the sum of three months' worth of ratings.

CARM Stock Forecast FAQ

What is CARM’s average 12-month price target, according to analysts?
Based on analyst ratings, Carisma Therapeutics’s 12-month average price target is 0.50.
    What is CARM’s upside potential, based on the analysts’ average price target?
    Carisma Therapeutics has 78.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CARM a Buy, Sell or Hold?
          Carisma Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Carisma Therapeutics’s price target?
            The average price target for Carisma Therapeutics is 0.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $0.50 ,the lowest forecast is $0.50. The average price target represents 78.57% Increase from the current price of $0.28.
              What do analysts say about Carisma Therapeutics?
              Carisma Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of CARM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis